GinoKInMDMPH

Oncology • Los Angeles, CA

Melanoma

Assistant Professor of Clinical Medicine and Dermatology, Division of Medical Oncology

Join to view full profile

Dr. In is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. In's full profile

Already have an account?

Office
1441 Eastlake Ave
Los Angeles, CA 90089
Phone+1 323-865-3105

Summary

Gino In, MD, is an experienced Oncologist based in Los Angeles, CA, with a subspecialty in Melanoma. His educational background includes a Fellowship in Medical Oncology from the University of Southern California/LAC+USC Medical Center and an MPH from Emory University Rollins School of Public Health. Currently, he works as a Physician at the LAC+USC Medical Center and as an Assistant Professor at the USC Norris Comprehensive Cancer Center. His areas of experience encompass conditions like basal cell carcinoma, acral-lentiginous melanoma and treatments such as immunotherapy. He has published numerous scholarly articles and has been involved in various clinical trials, primarily focusing on advanced skin cancer and melanoma.

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2013 - 2016
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 2011 - 2013
SUNY Downstate Health Sciences UniversityInternship, Internal Medicine, 2010 - 2011
Ross University School of MedicineClass of 2010
Emory University Rollins School of Public HealthMPH, Environmental and Occupational Health, 2004 - 2006
Emory UniversityBS, Biology, 1998 - 2002

Certifications & Licensure

CA State Medical License 2013 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma Start of enrollment: 2014 Mar 24
Active, not recruiting
Phase 1, Phase 2
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Start of enrollment: 2015 Mar 01
Completed
Phase 2
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery Start of enrollment: 2017 Feb 06
Active, not recruiting
Phase 2
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Start of enrollment: 2017 Jan 30
Active, not recruiting
Phase 2
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Start of enrollment: 2018 Jun 05
Active, not recruiting
Phase 2
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Start of enrollment: 2017 Sep 27
Active, not recruiting
Phase 2
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 Start of enrollment: 2017 Feb 09
Completed
Phase 1, Phase 2
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors Start of enrollment: 2017 Jun 01
Terminated
Phase 1, Phase 2
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma Start of enrollment: 2017 Dec 11
Terminated
Phase 3
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma Start of enrollment: 2018 May 30
Terminated
Phase 3
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma Start of enrollment: 2019 Feb 15
Active, not recruiting
Phase 2
Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial Start of enrollment: 2018 Nov 15
Suspended
Phase 3
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer Start of enrollment: 2019 May 17
Active, not recruiting
Phase 2
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer Start of enrollment: 2020 Jun 17
Recruiting
Phase 2
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy Start of enrollment: 2020 Aug 12
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma.
Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2024-10-23
Ancestry and somatic profile predict acral melanoma origin and prognosis.
Patricia Basurto-Lozada, Martha Estefania Vázquez-Cruz, Christian Molina-Aguilar, Amanda Jiang, Dekker C Deacon
Medrxiv. 2024-09-23
A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.
Annelise M Wilhite, Sharon Wu, Joanne Xiu, Geoffrey T Gibney, Thuy Phung
Gynecologic Oncology. 2024-09-01

Lectures

Molecular profiling of melanoma brain metastases (MBM) compared to primary cutaneous melanoma (CM).
2019 ASCO Annual Meeting - 6/1/2019

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member

Other Languages

Korean, Spanish

External Links

Faculty pagehttp://keck.usc.edu/faculty/gino-in/
Providers pagehttps://providers.keckmedicine.org/provider/Gino+Kim+In/250515